The trial was conducted on sixty adults with a diagnosis of either Mild Cognitive Impairment or mild/moderate Alzheimer's Disease, out of which 20 participants received placebo, 21 participants received insulin detemir (20 IU), and 19 participants received insulin detemir (40 IU) via a nasal drug delivery device, for 21 days. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.